Treatment regimens and survival among patients with head and neck squamous cell carcinoma from Mizo tribal population in northeast India - a single centre, retrospective cohort study

被引:0
|
作者
Zami, Zothan [1 ]
Pachuau, Lallianmawii [1 ]
Bawihtlung, Zothankima [2 ]
Khenglawt, Lalfakzuala [2 ]
Hlupuii, Lal [2 ]
Lalthanpuii, Cindy [2 ]
Hruaii, Vanlal [2 ]
Lalhruaitluanga, Hauhnar [1 ]
Kumar, Nachimuthu Senthil [1 ]
机构
[1] Mizoram Univ, Dept Biotechnol, Aizawl 796004, Mizoram, India
[2] Mizoram State Canc Inst, Aizawl 796017, Mizoram, India
关键词
Head and neck cancer; Induction chemotherapy; Concurrent chemoradiotherapy; Overall survival; Progression free survival; LOCALLY ADVANCED HEAD; INDUCTION CHEMOTHERAPY; CONCURRENT CHEMORADIOTHERAPY; CANCER; LEUKOCYTOSIS; RADIOTHERAPY; MARKER; N2;
D O I
10.1016/j.lansea.2024.100377
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Patients with early -stage head and neck squamous cell carcinoma (HNSCC) are treated using a singlemodality approach that involves either surgery (S) or radiotherapy (RT). Conversely, those with advanced -stage disease are treated using a multi -modality approach incorporating a combination of chemotherapy (CT), RT and S. In addition to behavioural factors, such as alcohol and tobacco use, clinical parameters, such as leukocyte and neutrophil counts and T and N classification, have been linked to the survival of patients with head and neck cancer. This retrospective study was designed to provide insights into the types of treatment (induction chemotherapy [IC], concurrent chemoradiotherapy [CCRT], S and RT) administered to patients with HNSCC in Mizoram, analyse their 2 -year outcome, and identify potential factors that may affect the response to treatment. Methods A retrospective cohort study was conducted using patients diagnosed with HNSCC between 2017 and 2020 in Mizoram, northeast India. Data on clinical and demographic factors and treatments provided were collected from medical records from the Mizoram State Cancer Institute, Mizoram. Overall survival (OS) and progression free survival (PFS) were determined for each factor using the Kaplan-Meier method and compared using the log-rank test. Cox regression analysis was used to identify the factors that affected OS and PFS. Multicollinearity test was performed between the predictors using a variance inflation factor cut-off point of 2. Findings A retrospective study was performed on 210 patients with HNSCC who were followed up for a period of 2 years. The findings revealed that hypopharynx was the most affected site, followed by the nasopharynx, oral cavity, oropharynx, and larynx. Regarding treatment regimens, 85/210 (40.5%) of the patients received IC along with CCRT or RT in a sequential manner. Moreover, 86/210 (41.0%) underwent CCRT alone, 22/210 (10.5%) received RT alone and 17/210 (8.1%) underwent surgery followed by adjuvant CCRT or RT. Two-year OS and PFS estimated using the Kaplan-Meier analysis were 78.1% (95% CI = 72.4%-84.2%) and 57.4% (95% CI = 50.8%-64.8%), respectively. Log- rank test showed that leucocytosis (p = 0.015) and neutrophilia (p = 0.014) exerted effects on OS, whereas nodal involvement (p = 0.005), neutrophilia (p = 0.043) and IC (p = 0.010) exerted effects on PFS. Multivariate analysis indicated that leucocytosis (p = 0.010 [OS], 0.025 [PFS]), neutrophilia (p = 0.029, 0.033), cancer site (laryngeal) (p = 0.009, 0.028) and nodal involvement (N2) (p = 0.020, 0.001) were predictors of poor OS and PFS. Interpretation OS was better than PFS in HNSCC patients from Mizo population. Multi -modality approach offered survival advantages over single -modality approach. Leucocytosis, neutrophilia, nodal involvement, and cancer sites were associated with poor OS and PFS. More comprehensive research with a larger sample size is needed to confirm the findings from this study. Health Asia Published https://doi.org/10. 1016/j.lansea.2024. 100377
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Factors predicting the development of distant metastases in patients with head and neck squamous cell carcinoma: A retrospective study from a single centre
    Gumusay, Ozge
    Ozet, Ahmet
    Buyukberber, Suleyman
    Baykara, Meltem
    Coskun, Ugur
    Cetin, Bulent
    Uner, Aytug
    Aydil, Utku
    Benekli, Mustafa
    JOURNAL OF BUON, 2015, 20 (02): : 521 - 526
  • [2] First-degree family history of cancer can be a potential risk factor among head and neck cancer patients in an isolated Mizo tribal population, northeast India
    Pachuau, Lallianmawii
    Zami, Zothan
    Nunga, Thanchung
    Zodingliana, R.
    Zoramthari, Rita
    Lalnuntluanga, R.
    Sangi, Zonun
    Rinmawii, Lal
    Kumar, Nachimuthu Senthil
    Lalhruaitluanga, H.
    CLINICAL EPIDEMIOLOGY AND GLOBAL HEALTH, 2022, 13
  • [3] xCT as a Predictor for Survival in a Population-Based Cohort of Head and Neck Squamous Cell Carcinoma
    Nissi, Linda
    Tuominen, Sanni
    Routila, Johannes
    Huusko, Teemu
    Ketonen, Petra
    Sundvall, Maria
    Leivo, Ilmo
    Irjala, Heikki
    Minn, Heikki
    Gronroos, Tove J.
    Ventela, Sami
    CANCER MEDICINE, 2024, 13 (21):
  • [4] Radiation Therapy Improves Survival in Patients with Distant Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Study
    Wang, Mengwen
    Zhao, Baitian
    Huang, Amin
    Song, Ming
    Wang, Jia
    Liu, Panpan
    JOURNAL OF CANCER, 2025, 16 (03): : 996 - 1007
  • [5] Social vulnerability and outcomes of head and neck cutaneous squamous cell carcinoma: A retrospective cohort study
    McCampbell, Lillian
    Fei-Zhang, David Jun
    Chelius, Daniel
    Hsia, Ling-Lun Bob
    Rastatter, Jeffrey
    Sheyn, Anthony
    JAAD INTERNATIONAL, 2024, 17 : 48 - 50
  • [6] Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study
    Vasiliadou, Ifigenia
    Breik, Omar
    Baker, Holly
    Leslie, Isla
    Sim, Van Ren
    Hegarty, Gemma
    Michaelidou, Andriana
    Nathan, Kannon
    Hartley, Andrew
    Good, James
    Sanghera, Paul
    Fong, Charles
    Urbano, Teresa Guerrero
    Lei, Mary
    Petkar, Imran
    Ferreira, Miguel Reis
    Nutting, Chris
    Wong, Kee Howe
    Newbold, Kate
    Harrington, Kevin
    Bhide, Shree
    Kong, Anthony
    CANCERS, 2021, 13 (06) : 1 - 12
  • [7] Survival outcomes in head and neck squamous cell carcinoma of unknown primary: A national cohort study
    Hardman, John C.
    Constable, James
    Dobbs, Sian
    Hogan, Christopher
    Hulse, Kate
    Khosla, Shivun
    Milinis, Kristijonas
    Tudor-Green, Ben
    Williamson, Andrew
    Paleri, Vinidh
    CLINICAL OTOLARYNGOLOGY, 2024, 49 (05) : 604 - 620
  • [8] Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution
    Fayette, Jerome
    Montella, Anthony
    Chabaud, Sylvie
    Bachelot, Thomas
    Pommier, Pascal
    Girodet, Didier
    Racadot, Severine
    Montbarbon, Xavier
    Favier, Bertrand
    Zrounba, Philippe
    ANTI-CANCER DRUGS, 2010, 21 (05) : 553 - 558
  • [9] Survival study and treatment strategy for second primary malignancies in patients with head and neck squamous cell carcinoma and nasopharyngeal carcinoma
    Tsou, Yung-An
    Hua, Chun-Hung
    Tseng, Hsien-Chang
    Lin, Meng-Hung
    Tsai, Ming-Hsui
    ACTA OTO-LARYNGOLOGICA, 2007, 127 (06) : 651 - 657
  • [10] Association of Delayed Time to Treatment Initiation With Overall Survival and Recurrence Among Patients With Head and Neck Squamous Cell Carcinoma in an Underserved Urban Population
    Liao, David Z.
    Schlecht, Nicolas F.
    Rosenblatt, Gregory
    Kinkhabwala, Corin M.
    Leonard, James A.
    Ference, Ryan S.
    Prystowsky, Michael B.
    Ow, Thomas J.
    Schiff, Bradley A.
    Smith, Richard V.
    Mehta, Vikas
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2019, 145 (11) : 1001 - 1009